Asset Details
Do you wish to reserve the book?
Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
Do you wish to request the book?
Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
2019
Overview
Objective
To determine the cutoffs that optimized the agreement between 18F‐Florbetapir positron emission tomography (PET) and Aβ1‐42, Aβ1‐40, tTau, pTau and their ratios measured in cerebrospinal fluid (CSF) on the LUMIPULSE G600II instrument, we quantified the levels of these four biomarkers in 94 CSF samples from participants of the Sant Pau Initiative on Neurodegeneration (SPIN cohort) using the Lumipulse G System with available 18F‐Florbetapir imaging.
Methods
Participants had mild cognitive impairment (n = 35), AD dementia (n = 12), other dementias or neurodegenerative diseases (n = 41), or were cognitively normal controls (n = 6). Levels of Aβ1‐42 were standardized to certified reference material. Amyloid scans were assessed visually and through automated quantification. We determined the cutoffs of CSF biomarkers that optimized their agreement with 18F‐Florbetapir PET and evaluated concordance between markers of the amyloid category.
Results
Aβ1‐42, tTau and pTau (but not Aβ1‐40) and the ratios with Aβ1‐42 had good diagnostic agreement with 18F‐Florbetapir PET. As a marker of amyloid pathology, the Aβ1‐42/Aβ1‐40 ratio had higher agreement and better correlation with amyloid PET than Aβ1‐42 alone.
Interpretation
CSF biomarkers measured with the Lumipulse G System show good agreement with amyloid imaging in a clinical setting with heterogeneous presentations of neurological disorders. Combination of Aβ1‐42 with Aβ1‐40 increases the agreement between markers of amyloid pathology.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ Alzheimer Disease - cerebrospinal fluid
/ Alzheimer Disease - diagnosis
/ Alzheimer Disease - metabolism
/ Amyloid beta-Peptides - cerebrospinal fluid
/ Cognitive Dysfunction - cerebrospinal fluid
/ Cognitive Dysfunction - diagnosis
/ Cognitive Dysfunction - metabolism
/ Dementia
/ Dementia - cerebrospinal fluid
/ Female
/ Humans
/ Male
/ Plaque, Amyloid - diagnostic imaging
/ Plaque, Amyloid - metabolism
